Rădulescu Patricia Mihaela, Căluianu Elena Irina, Traşcă Emil Tiberius, Mercuţ Dorin, Georgescu Ion, Georgescu Eugen Florin, Ciupeanu-Călugăru Eleonora Daniela, Mercuţ Maria Filoftea, Mercuţ Răzvan, Padureanu Vlad, Streba Costin Teodor, Călăraşu Cristina, Rădulescu Dumitru
UMF Craiova Doctoral School, University of Pharmacy and Medicine Craiova, 200349 Craiova, Romania.
General Surgery Department, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Diagnostics (Basel). 2023 Jul 22;13(14):2446. doi: 10.3390/diagnostics13142446.
We aimed to evaluate the outcomes and survival of patients with acute pancreatitis who shared the same clinical form, age, and sex before the pandemic, during the pandemic, and among those with confirmed COVID-19 infection upon hospital admission. This consideration used the sparse data in the existing literature on the influence of the pandemic and COVID-19 infection on patients with acute pancreatitis. To accomplish this, we conducted a multicentric, retrospective case-control study using propensity score matching with a 2:1 match of 28 patients with SARS-CoV-2 infection and acute pancreatitis, with 56 patients with acute pancreatitis pre-pandemic, and 56 patients with acute pancreatitis during the pandemic. The study outcome demonstrated a six-fold relative risk of death in patients with acute pancreatitis and SARS-CoV-2 infection compared to those with acute pancreatitis before the pandemic. Furthermore, restrictive measures implemented during the pandemic period led to a partial delay in the care of patients with acute pancreatitis, which likely resulted in an impairment of their immune state. This, in certain circumstances, resulted in a restriction of surgical treatment indications, leading to a three-fold relative risk of death in patients with acute pancreatitis during the pandemic compared to those with acute pancreatitis before the pandemic.
我们旨在评估在大流行之前、大流行期间以及入院时确诊为COVID-19感染的急性胰腺炎患者的结局和生存率，这些患者具有相同的临床症状、年龄和性别。这一考量是基于现有文献中关于大流行和COVID-19感染对急性胰腺炎患者影响的稀疏数据。为实现这一目标，我们进行了一项多中心回顾性病例对照研究，采用倾向评分匹配法，将28例感染SARS-CoV-2且患有急性胰腺炎的患者与56例大流行前患有急性胰腺炎的患者以及56例大流行期间患有急性胰腺炎的患者按2:1进行匹配。研究结果表明，与大流行前患有急性胰腺炎的患者相比，感染SARS-CoV-2且患有急性胰腺炎的患者死亡的相对风险高出六倍。此外，大流行期间实施的限制措施导致急性胰腺炎患者的治疗出现部分延迟，这可能导致其免疫状态受损。在某些情况下，这导致手术治疗指征受限，与大流行前患有急性胰腺炎的患者相比，大流行期间患有急性胰腺炎的患者死亡的相对风险高出三倍。
